UPDATE: Replimune (REPL) - The FDA Blinks

Regulatory Resurrection and a Path Back to Approval

Executive Summary: The Bear Case Unwinds

On April 10, I called this one Dead Money. The FDA had just issued its second Complete Response Letter on RP1, the CEO had said development was “not viable” without accelerated approval, and management was announcing layoffs and a manufacturing scale-back. The stock was $4.76 and the wind-down runway looked obvious.

Today, the stock closed at $8.69 — up 82.6% from the April CRL low. The FDA has reversed course. Replimune is resubmitting the BLA “in the coming days,” and the agency has agreed to treat it as urgent and prioritize review. The hammer that dropped in April is being lifted.

The Receipts

The Reversal (May 29). Replimune announced that “following collaborative communications with the FDA,” the company and the agency have “aligned on a path forward for resubmission and reconsideration” of the RP1 + nivolumab BLA in advanced melanoma. The implication: the same agency that, per management’s April blistering press release, “refused to meet with the company during the entire review process” is now back at the table.

The Priority Review Signal. The FDA has indicated it “will treat the BLA resubmission as an urgent matter upon receipt and will prioritize its review in recognition of the significant unmet need.” Why it matters: this is not a polite acknowledgment letter. This is the agency telegraphing that the resubmission will not sit in a queue for ten months. The ~8,500 annual U.S. advanced melanoma deaths and the ~50% PD-1 failure rate the press release leads with are the unmet-need framing the FDA appears to have accepted.

The Tone Shift. Compare April’s “inconsistent communication and a fragmented and slow-moving regulatory process” to today’s CEO quote: “We are grateful to the FDA leadership for their willingness to engage in a collaborative dialogue.” This is corporate-speak for “they took our call, and the conversation went well.” Management does not pivot from public indictment to public gratitude in seven weeks unless something material has changed behind the scenes.

What is NOT in the release. No mention of new data. No mention of a modified label scope. No mention of whether IGNYTE-3 interim data is being substituted in. The resubmission is, as best I can tell, the same IGNYTE single-arm package — but now with an FDA that appears willing to reconsider it. That’s either a policy shift at the agency level (plausible under the current administration’s noisy posture on FDA process) or a negotiated compromise we’ll only see in the eventual approval letter.

The Scientific Reality Check

The clinical data hasn’t changed. The 33.6% ORR in IGNYTE vs. the ~11% historical control for anti-PD-1 failed melanoma is the same data the FDA twice called “not considered to be an adequate and well-controlled clinical investigation.” The 24.8-month median duration of response is the same number.

What appears to have changed is the FDA’s willingness to weigh that data against the unmet need. In the February deep dive I wrote that “in the modern FDA era (Project FrontRunner), single-arm approvals are becoming exceptionally rare.” That observation may need a footnote — the agency seems to be carving out a path here, even if it’s framed as a one-off accommodation rather than a doctrinal shift.

The bear-case scenario I laid out in April — that “Replimune simply does not have the capital to fund [randomized Phase 3 trials] to completion” — is now less binding. If accelerated approval lands in the next few months, the commercial revenue and the optionality to raise non-distressed capital both come back online. The wind-down runway becomes a launch runway.

The Mea Culpa

I called the April CRL the death of single-arm approvals and the death of RP1. The first claim may still be directionally right; the second was wrong, or at least premature. Readers who held through the April puke — or worse, who took my “Sell” at heart and exited near $4.76 — deserve the acknowledgment. The stock is now back above where it traded before the April CRL, and the platform thesis (RP1 → RP2 → ARTACUS niche) is back in play.

Two things I’ll defend from the April post: the regulatory risk was real, and the company’s own admission that RP1 was “not viable” without accelerated approval was the right thing to take at face value at the time. Reversing on new information is not the same as having been wrong on the analysis. But the verdict needs to reverse with the facts.

The Risks Still on the Table

• No PDUFA date yet. “In the coming days” for resubmission and “prioritize review” for the agency are not a calendar. Until the FDA accepts the resubmission and assigns a goal date, this is still a promise of speed rather than speed itself.

• Cash position. December 31, 2025 cash was $269.1M with runway “into Q1 2027.” That was before April’s restructuring, severance, and manufacturing scale-back charges. The post-April balance sheet may be materially thinner, and the next 10-Q will matter. A non-distressed capital raise on this rally now looks likely — and arguably prudent.

• The label. Even if approved, the FDA could carve the label narrowly enough to constrain the commercial opportunity below the ~10,000-patient TAM I outlined in February.

• The platform contagion risk inverts. I wrote in February that “if the FDA completely rejects RP1’s clinical utility… the entire RP2 pipeline will likely suffer a catastrophic credibility contagion.” That contagion partially fired in April. It now partially unwinds — but the RP2 HCC monotherapy data expected by end of 2026 is still the next real test of the platform.

The Updated Verdict

Previous Verdict (April 10): SELL / DEAD MONEY. Current Stance: SELL → SPECULATIVE BUY.

The rationale:

• The FDA’s willingness to prioritize the resubmission materially de-risks the regulatory tail that justified the April Sell call.

• The 33.6% ORR / 24.8-month DOR data, paired with an engaged review team, could plausibly produce an approval on a months — not years — timeline.

• The platform optionality (RP2 in uveal melanoma, HCC monotherapy data end of 2026, the ARTACUS solid-organ-transplant niche) re-attaches to the equity if RP1 lands.

• The stock has already moved 82.6% off the lows, so this is not a fresh asymmetric setup — much of the easy money has been made by anyone who faded the April panic.

For those who exited in April: this looks like a setup that may warrant a small, sized-for-volatility re-entry rather than a chase. For those who held through: the thesis is back, but the next genuine catalyst is FDA acceptance of the resubmission and a new PDUFA date — that’s what to watch for before sizing up.

This remains a binary-event name. The agency has signaled willingness; it has not yet signaled approval. Size accordingly.

This post is for informational and educational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. The author is a medicinal chemist, not a licensed financial advisor; the scientific analysis herein should not be interpreted as medical guidance. Biotech investing is inherently volatile — past scientific validation and early clinical data do not guarantee future late-stage clinical success or regulatory approval. Do your own due diligence.